Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)
Shots:
- Boehringer Ingelheim has signed an agreement with Quallent Pharmaceuticals to expand the access of citrate-free adalimumab-adbm, a biosimilar to Humira (adalimumab), across the US
- As per the agreement, BI will handle the manufacturing activity of adalimumab-adbm for Quallent and will continue the commercialization of Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm
- Quallent will provide high-concentration (40mg/0.4mL) and low-concentration (40mg/0.8mL) citrate-free adalimumab-adbm in a pre-filled syringe or pen. Furthermore, Quallent's 40mg/0.8mL private-labeled adalimumab-adbm will share Adalimumab-adbm's interchangeability designation
Ref: PR Newswire | Image: Boehringer Ingelheim
Related News:- The US FDA Approves High Concentration of Boehringer Ingelheim's Cyltezo (Biosimilar, Humira)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
